UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Lung transplantation: Deceased donor evaluation and management

Author
Edward R Garrity, MD, MBA
Section Editor
Elbert P Trulock, MD
Deputy Editor
Helen Hollingsworth, MD

INTRODUCTION

Optimal selection and care of donor lungs for transplant are needed to increase the number of available lungs. Deceased donor evaluation, selection, and management after brain and cardiac death will be reviewed here from the lung transplant perspective. Living donor lobar transplants are rare in comparison to deceased donor lung transplants.

The indications for lung transplantation, selection of lung transplant recipients, and donor lung preservation are discussed separately. (See "Lung transplantation: An overview" and "Lung transplantation: General guidelines for recipient selection" and "Lung transplantation: Donor lung preservation".)

DONATION AFTER BRAIN DEATH

Donor evaluation begins with the notification of the local Organ Procurement Organization (OPO) of a potential donor. A member of the OPO, or a provider trained in the consent of families for organ donation, should approach the family as soon as reasonable after the determination of brain death [1]. (See "Diagnosis of brain death".)

When the patient has signed an irrevocable consent for transplant (offered through some state registries), the OPO staff will support the family through the organ retrieval and grieving process. If consent has not already been provided by the patient, the OPO staff will explain the procurement process to the family, including the dignity of the process and implications for funeral arrangements, and obtain their consent [2]. The OPO staff will also coordinate evaluation of the donor for suitability for transplant and will communicate with the United Network for Organ Sharing (UNOS) to match the donor with an appropriate recipient from the waiting list. (See "Lung transplantation: An overview".)

DONATION AFTER CARDIAC DEATH

Donation after cardiac death (also called nonheartbeating donor) has become an accepted method of increasing the donor pool in some transplant centers and organ procurement organizations (OPO), although the exact definition of cardiac death and the timing of organ harvest remain controversial. Nonheartbeating donors can be classified according to the Maastricht system, which was developed in 1995 and revised in 2003 [3,4]:

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Jun 27 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001; 344:1215.
  2. Medicare and Medicaid Programs; Conditions for Coverage for Organ Procurement Organizations (OPOs); Final Rule. Services, DoHaH (Ed), Federal Register May 31, 2006.
  3. Kootstra G. Statement on non-heart-beating donor programs. Transplant Proc 1995; 27:2965.
  4. www.unos.org/SharedContentDocuments/Policy-Notice-March-2007-BOD-Meeting(a)(1).pdf - 2008-03-18 (Accessed on January 01, 2009).
  5. Bernat JL, Capron AM, Bleck TP, et al. The circulatory-respiratory determination of death in organ donation. Crit Care Med 2010; 38:963.
  6. Steen S, Sjöberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357:825.
  7. Gries CJ, White DB, Truog RD, et al. An official American Thoracic Society/International Society for Heart and Lung Transplantation/Society of Critical Care Medicine/Association of Organ and Procurement Organizations/United Network of Organ Sharing Statement: ethical and policy considerations in organ donation after circulatory determination of death. Am J Respir Crit Care Med 2013; 188:103.
  8. 2012 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) Annual Report http://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/06_lung_13.pdf.
  9. Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.
  10. Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Recommendations for nonheartbeating organ donation. A position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 2001; 29:1826.
  11. Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. JAMA 1981; 246:2184.
  12. Robertson JA. The dead donor rule. Hastings Cent Rep 1999; 29:6.
  13. Krutsinger D, Reed RM, Blevins A, et al. Lung transplantation from donation after cardiocirculatory death: a systematic review and meta-analysis. J Heart Lung Transplant 2015; 34:675.
  14. De Oliveira NC, Osaki S, Maloney JD, et al. Lung transplantation with donation after cardiac death donors: long-term follow-up in a single center. J Thorac Cardiovasc Surg 2010; 139:1306.
  15. Castleberry AW, Worni M, Osho AA, et al. Use of lung allografts from brain-dead donors after cardiopulmonary arrest and resuscitation. Am J Respir Crit Care Med 2013; 188:466.
  16. Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest 2012; 141:451.
  17. Eberlein M, Reed RM, Permutt S, et al. Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation. J Heart Lung Transplant 2012; 31:1207.
  18. Mason DP, Batizy LH, Wu J, et al. Matching donor to recipient in lung transplantation: How much does size matter? J Thorac Cardiovasc Surg 2009; 137:1234.
  19. Eberlein M, Reed RM, Bolukbas S, et al. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation. J Heart Lung Transplant 2015; 34:233.
  20. Shigemura N, Bermudez C, Hattler BG, et al. Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant 2009; 28:130.
  21. Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199.
  22. Garrity ER Jr, Boettcher H, Gabbay E. Donor infection: an opinion on lung donor utilization. J Heart Lung Transplant 2005; 24:791.
  23. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2:761.
  24. UNOS Allocation of Deceased Kidneys Policy, 2007 http://www.unos.org/policiesandbylaws/policies.asp?fromPage=Policy.31 (Accessed on February 11, 2008).
  25. Whiting D, Banerji A, Ross D, et al. Liberalization of donor criteria in lung transplantation. Am Surg 2003; 69:909.
  26. Pierre AF, Sekine Y, Hutcheon MA, et al. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002; 123:421.
  27. D'Armini AM, Boffini M, Zanotti G, et al. "Twinning procedure" in lung transplantation: influence of graft ischemia on survival and incidence of complications. Transplant Proc 2004; 36:654.
  28. Aigner C, Winkler G, Jaksch P, et al. Extended donor criteria for lung transplantation--a clinical reality. Eur J Cardiothorac Surg 2005; 27:757.
  29. Lardinois D, Banysch M, Korom S, et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg 2005; 27:762.
  30. Reyes KG, Mason DP, Thuita L, et al. Guidelines for donor lung selection: time for revision? Ann Thorac Surg 2010; 89:1756.
  31. Sommer W, Kühn C, Tudorache I, et al. Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm. J Heart Lung Transplant 2013; 32:1065.
  32. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22:1183.
  33. Bittle GJ, Sanchez PG, Kon ZN, et al. The use of lung donors older than 55 years: a review of the United Network of Organ Sharing database. J Heart Lung Transplant 2013; 32:760.
  34. Salerno CT, Burdine J, Perry EH, et al. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation 1998; 65:261.
  35. Yu NC, Haug MT 3rd, Khan SU, et al. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? J Heart Lung Transplant 1999; 18:764.
  36. Taghavi S, Jayarajan SN, Furuya Y, et al. Single Lung Transplantation with ABO Compatible Donors Results in Excellent Outcomes. J Heart Lung Transplant 2014.
  37. Taghavi S, Jayarajan SN, Furuya Y, et al. Single-lung transplantation with ABO-compatible donors results in excellent outcomes. J Heart Lung Transplant 2014; 33:822.
  38. Low M, Gregory G. Passenger lymphocyte syndrome after lung transplant. Blood 2012; 120:4122.
  39. Horlait G, Bulpa P, Evrard P. Passenger lymphocyte syndrome mimicking hemolytic uremic syndrome after lung transplantation. J Heart Lung Transplant 2013; 32:271.
  40. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710.
  41. de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003; 75:367.
  42. Berman M, Goldsmith K, Jenkins D, et al. Comparison of outcomes from smoking and nonsmoking donors: thirteen-year experience. Ann Thorac Surg 2010; 90:1786.
  43. Bonser RS, Taylor R, Collett D, et al. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012; 380:747.
  44. Taghavi S, Jayarajan SN, Komaroff E, et al. Single-lung transplantation can be performed with acceptable outcomes using selected donors with heavy smoking history. J Heart Lung Transplant 2013; 32:1005.
  45. Healey PJ, Davis CL. Transmission of tumours by transplantation. Lancet 1998; 352:2.
  46. Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7:2652.
  47. Ridgeway AL, Warner GS, Phillips P, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med 1996; 153:1166.
  48. Organ Procurement and Transplantation Network. Guidance for organ donation and transplantation professionals regarding the Zika virus https://optn.transplant.hrsa.gov/news/guidance-for-organ-donation-and-transplantation-professionals-regarding-the-zika-virus/. (Accessed on March 14, 2016).
  49. Silveira FP, Campos SV. The Zika epidemics and transplantation. J Heart Lung Transplant 2016; 35:560.
  50. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.
  51. UNOS. Critical Pathway for the Organ Donor http://www.unos.org/resources/donorManagement.asp?index=2 (Accessed on February 03, 2009).
  52. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85:278.
  53. Miñambres E, Pérez-Villares JM, Chico-Fernández M, et al. Lung donor treatment protocol in brain dead-donors: A multicenter study. J Heart Lung Transplant 2015; 34:773.
  54. Avlonitis VS, Wigfield CH, Kirby JA, Dark JH. The hemodynamic mechanisms of lung injury and systemic inflammatory response following brain death in the transplant donor. Am J Transplant 2005; 5:684.
  55. Ullah S, Zabala L, Watkins B, Schmitz ML. Cardiac organ donor management. Perfusion 2006; 21:93.
  56. Salim A, Martin M, Brown C, et al. The effect of a protocol of aggressive donor management: Implications for the national organ donor shortage. J Trauma 2006; 61:429.
  57. SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.
  58. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002; 2:701.
  59. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA 2010; 304:2620.
  60. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482.
  61. Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. J Heart Lung Transplant 2009; 28:480.
  62. Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med 2003; 31:1113.
  63. Anraku M, Cameron MJ, Waddell TK, et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008; 8:2140.
  64. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:4ra9.